Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Románia3. fázis

Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

A legfontosabb adatok

Ki végzi
Mabxience Research S.L.
Hol
Craiova (Románia)A helyszín megnézéseMég 6 másik országban, 21 helyszínen
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
119 fő, tervezett
Kezdés
2025. dec. 30.
Várható befejezés
2028. jan. 31.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. június 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek előrehaladott (III. vagy IV. stádiumú) melanomájuk van, amely műtéttel nem távolítható el, vagy áttétet adott, és a betegségükre még nem kaptak kezelést.

Életkor
18 éves vagy idősebb
Nem
Minden nem
A betegség stádiuma
Szövettanilag igazolt, még nem kezelt, műtéttel nem eltávolítható III. vagy IV. stádiumú melanoma, legalább 1 mérhető elváltozással CT-n vagy MRI-n. ECOG teljesítménystátusz: 0 vagy 1. Várható élettartam legalább 3 hónap. Testsúly legalább 50 kg (110 lb).
Korábbi kezelés
Az előrehaladott melanomára korábban nem kaphatott szisztémás kezelést. Korábban nem kaphatott immunterápiát (például anti-PD-1, anti-PD-L1 vagy anti-CTLA-4), sem BRAF-célzott kezelést. A korábbi stádiumra kapott szisztémás kezelés megengedett, ha a kezelés vége óta legalább 1 éve nincs betegség.
Biomarker vagy leletérték
A randomizálás előtt legfeljebb 90 nappal vett daganatszövet-mintának rendelkezésre kell állnia a PD-L1 vizsgálathoz. A BRAF-mutáció állapota bármilyen lehet.

A részvétel fő kizáró okai

  • Agyi áttét vagy leptomeningealis áttét
  • Szemi, nyálkahártyai vagy acralis lentiginosus melanoma
  • Jelenlegi vagy korábbi másik daganatos betegség (néhány kivétellel)
  • Az elmúlt 2 évben szisztémás kezelést igénylő aktív autoimmun betegség
  • Pozitív HIV-, hepatitis B- vagy hepatitis C-teszt, vagy szervátültetés vagy őssejt-átültetés

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years at the time of signing the informed consent (or adulthood where the legalage of majority in the country is established >18 years)
  • Any BRAF mutation status is allowed (BRAF-mutated, BRAF wild-type or non-mutated, or BRAF status unknown)
  • Adequate organ function (bone marrow, hepatic, renal, haematologic, endocrine, and coagulation function) should be demonstrated during the screening period. This is defined as: a. Haematologic function: absolute neutrophil count ≥1.5 × 109/L, platelets ≥100 × 109 /L, and haemoglobin ≥9 g/dL. ** Subjects should not have received RBC transfusion prior to 14 days before screening labs. b. Renal function: GFR (using CKD-EPI-2021) ≥ 60 mL/min/1.73 m2 . c. Liver function: total bilirubin level ≤1.5 × ULN (except subjects with Gilbert Syndrome, who can have total bilirubin <3.0 mg/dL), albumin level ≥LLN, AST/ALT ≤2.5 × ULN (≤5 × ULN for subjects with liver metastases). d. Endocrine function: TSH within normal limits. If TSH is not within normal limits, the subject may still be eligible if free T3 and free T4 are within normal limits. e. Coagulation: INR ≤ 1.5 and aPTT ≤1.5 × ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must be on a stable anticoagulation regimen and have an INR not above the target therapeutic range for the 14 days preceding the start of the study drug
  • Female subjects of childbearing potential and their partners, as well as male subjects with female partners of childbearing potential and their partners, must agree to adhere to the use of a highly effective method of contraception during the study and for at least 5 months after the last dose of nivolumab. Refer to Appendix 15.1 for contraception guidance
  • Non-fertile females can be included
  • Body weight ≥50 kg at baseline
  • Signed informed consent must be obtained before initiation of any study-specific procedures or treatment
  • ECOG performance status of 0 or 1
  • Life expectancy for at least 3 months
  • Untreated, histologically confirmed advanced unresectable Stage III or Stage IV melanoma, as per AJCC 8th Edition staging system. Prior melanoma systemic therapy for earlier stages is allowed for patients who have been disease-free for at least 1 year after end of therapy, except if therapy included use of prohibited medications. Prior use of immune therapies (adjuvant or neoadjuvant) is not allowed as per Exclusion Criteria #2
  • At least 1 measurable disease lesion by CT or MRI per RECIST v1.1 criteria
  • Tumour tissue from an unresectable or metastatic site of disease, collected within 90 days prior to randomisation, must be available and provided for PD-L1 testing. All samples must be classified as negative (<1%) or PD-L1 positive (≥1% to <5% or ≥5%). If only the old sample >90 days is available and there is no possibility of having a new biopsy sample, then the subject will be excluded
  • In the case of prior palliative radiotherapy (on metastatic lesions), this must have been completed at least 2 weeks prior to the study drug administration. No adjuvant radiation therapies are allowed

Ki nem vehet részt

  • Subjects receiving any prior systemic therapy for advanced, unresectable, or metastatic Stage III or Stage IV melanoma (except for palliative radiotherapy, in accordance with Inclusion Criteria #9)
  • Any diagnosis of immunodeficiency, systemic steroid therapy (replacement therapy outlined in Exclusion Criteria #8, inhaled, intranasal, intraocular, or topical steroids are allowed) or any other form of immunosuppressive therapy within 7 days prior to the first dose of the study drug
  • Any major surgery (eg, hip or spine surgery) less than 28 days prior to the first dose of the study drug
  • Having received a solid organ/tissue allogeneic or haematopoietic transplant
  • Any active or previous infection requiring therapy (oral or systemic) within 30 days prior to the first dose of the study drug
  • Have received or are about to receive a live virus vaccination within 30 days prior to the first dose of the study drug. Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted
  • At the time of signing the informed consent, the subject is a regular user (including “recreational use”) of any illicit drug or have a recent history (within the past year) of substance abuse (including alcohol)
  • Be pregnant or lactating or expecting to conceive during the study or up to 5 months after the last dose of the study drug
  • Subjects receiving any prior immunotherapy (regardless of the melanoma stage), such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-LAG or anti-CTLA-4 therapy (including ipilimumab or any other antibody or drug that specifically targets costimulation of T-cells or immune checkpoints) and/or BRAF-targeted therapy
  • Participation in another clinical study or treatment with another investigational agent within 4 weeks or 5 elimination half-lives prior to randomisation (whichever is longer)
  • Brain metastases or leptomeningeal metastases. A negative brain imaging of less than 90 days prior to screening is required
  • History and/or current interstitial lung disease or pneumonitis (non-infectious) requiring oral or IV steroids or another immunosuppressive drug
  • Positive serology for human immunodeficiency virus (HIV 1/2), hepatitis B (HBsAg positive and/or HBcAb positive, and HBV DNA positive, refer to Section 8.3.2.1) or hepatitis C (HCVAb positive and HCV RNA positive). In addition, subjects with untreated positive serology for Strongyloides spp will be excluded
  • Inability to comply with protocol procedures and/or any other acute or chronic medical condition that may increase the risk for the subject associated with study participation or study drug administration, that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study
  • History of another malignancy or a concurrent malignancy. Exceptions include subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ
  • Active autoimmune disease that has required systemic treatment in the last 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin or physiological corticosteroid replacement therapy for pituitary or adrenal insufficiency [daily prednisone at a dose of ≤10 mg or equivalent]) is not considered a form of systemic treatment
  • Known active TB or untreated latent TB
  • Immediate family member who is at the research site or sponsoring staff who is directlyninvolved in this study
  • Peritoneal melanomatosis
  • Ocular melanoma, mucosal melanoma and acral lentiginous melanoma
  • Subjects with hyperthyroidism or hypothyroidism are excluded but those subjects who are stable on hormone replacement will be allowed

Ez a vizsgálat jelenleg itt érhető el: Románia.

Még 6 másik országban, 21 helyszínen

  • Centrul De Oncologie SF Nectarie S.R.L.Craiova, RomániaRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

To establish the PK bioequivalence between MB11 and EU-/US-Opdivo and to demonstrate similar efficacy between MB11 and Opdivo administered as first-line treatment in adult subjects with untreated, unresectable, or metastatic Stage III or Stage IV melanoma.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
A regiszteradat frissítve
2026. június 4.